期刊文献+

OX40/OX40L与疾病 被引量:3

OX40/OX40L and Diseases
下载PDF
导出
摘要 OX40/OX40L是机体免疫应答过程中一对重要的协同刺激分子,参与T细胞的活化、增殖和迁移,以及生发中心的形成和树突状细胞的分化成熟。在介导肿瘤免疫应答和自身免疫疾病的发生、发展中具有重要作用。OX40只表达于活化的T细胞表面,且主要是CD4+T细胞。OX40+T细胞是抗原特异性T细胞,集中于淋巴组织的T细胞区和外周的炎性位点,非炎性相关组织及外周血中很少出现,有很强的区域特异性。OX40L能协同刺激T细胞的活化,促进B细胞产生高效价抗体和类别转化,介导OX40+T细胞向炎症部位浸润。 OX40/OX40L are a pair of important allostimulatory factors in the process of immune response,which participate T-cell′s activation,proliferration and migration,as well as the formation of germinal center and the dendritic cell maturation.They play an important role in mediating tumor immune response and autoimmune disease.OX40 can only be expressed on activated T cell,mainly CD4 +T cells.OX40+T cells are antigenic specific T cells,which focus on T cell area of lymphatic organization and peripheral inflammatory sites,non-inflammatory organizations and rarely peripheral blood.OX40+ cells have very strong regional specificity.OX40L can allositimulate T cell activation,promote B cells to produce high potency antibodies and category transformation,mediate OX40+T cells to infiltrate inflammations.
作者 刘纯 王玉亮
出处 《医学综述》 2011年第15期2271-2273,共3页 Medical Recapitulate
关键词 OX40 OX40L 炎性疾病 自身免疫性疾病 肿瘤 移植免疫 OX40 OX40L Inflammatory disease Autoimmune disease Tumor Transplantation immunology
  • 相关文献

参考文献7

二级参考文献59

  • 1WANG Guangming FENG Yougang HAO Jie LI Ailing GAO Xiang XIE Shusheng.Induction of xenogeneic islet transplantation tolerance by simultaneously blocking CD28-B7 and OX40-OX40L co-stimulatory pathways[J].Science China(Life Sciences),2005,48(5):515-522. 被引量:4
  • 2王晓娣,吴铁镛.OX40在溃疡性结肠炎中的表达及意义[J].中日友好医院学报,2006,20(3):137-140. 被引量:5
  • 3张印则,熊文,李桢,邵超鹏,李天君,赵锋,杨宝成.不同相对分子质量mPEG-SPA修饰血小板CD42a效果差异分析[J].南方医科大学学报,2007,27(3):392-393. 被引量:3
  • 4魏连波 刘冠贤 等.肾脏病临床备要[M].北京:人民卫生出版社,1997.320.
  • 5Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways[J]. Nature, 1996, 381 (6581): 434-438.
  • 6Li XC, Strom TB. Blocking T-cell costimulation in transplantation: opportunities and challenges[J]. Transfusion, 2000, 40:139-142.
  • 7Watts TH, DeBenedette MA. T cell co-stimulatory molecules other than CD28[J]. Curr Opin Immunol, 1999, 11 (3): 286-293.
  • 8Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40[J]. Nat Rev Immunol, 2004, 4: 420-431.
  • 9Tania H W. TNF/TNFR family members in costimulation of T cell response[J]. Annu Rev Immunol, 2005, 23: 23-68.
  • 10Yuan X, Salama AD, Dong V, et al. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo[J]. J Immunol, 2003, 170: 2949-2955.

共引文献7

同被引文献23

  • 1Mavragani CP, Schini M, Gravani F, et al. Brief report: Adrenalautoimmunity in primary SjOgreny s syndrome [ J ] . Arthritis Rheum,2012,64(12) : 4066-4071.
  • 2Qin W, Hongya W, Yongjing C, et al. Increased 0X40 and soluble0X40 ligands in children with Henoch-Schonlein purpura : associationwith renal involvement[ J]. Pediatr Allergy Immunol,2011, 22( 1 Pt1): 54 -59.
  • 3Fang X,Qin W, XueGuang Z,et al. Costimulatory molecule 0X40/0X40L expression in ductal carcinoma in situ and invasive ductalcarcinoma of breast: An immunohistochemistry-based pilot study [ J].Pathol Res Pract, 2010,206(11) : 735 -739.
  • 4Nguyen CQ, Cornelius JG, Cooper L, et al. Identification of possiblecandidate genes regulating SjOgren,s syndrome-associated autoimmunity : apotential role for TNFSF4 in autoimmune exocrinopathy [ J ]. ArthritisRes Ther,2008, 10(6) : R137.
  • 5Weinberg AD, Vella AT,Crof M. 0X40: life beyond the effector Tcell stage[ J]. Semin Immunol, 1998, 10(6) : 471 -480.
  • 6Yan JC, Chen GH, Gong J, et al. Up-regulation of OX40-OX40Lsystem on T lympho-cytes in patients with acute coronary syndromes[J]. J Cardiovasc Pharmacol,2009, 54(5) : 451 -455.
  • 7Manku H, Graham DS, Vyse TJ. Association of the co-stimulator0X40L with systemic lupus erythematosus[ J]. J Mol Med, 2009,87(3): 229-234.
  • 8Rogers PR, Croft M. CD28, 0X40,LFA-1 and CD4 modulation ofThl/Th2 differentiation is directly dependent on the dose of antigen[J]. J Immunol, 2000, 164(6) : 2955 -2963.
  • 9Ishii N, Takahashi T, Soroosh P, et al. 0X40-0X40 ligand interac-tion in T-cell-mediated immunity and immunopathology [ J ]. AdvImmunol, 2010,105 : 63 -98.
  • 10Ito T,Wang YH,Duramad O,et al. 0X40 ligand shuts down IL-10-producing regulatory T cells[ J]. Proc Natl Acad Sci U S A, 2006,103(35) : 13138 -13143.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部